Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
MBRX

MBRX - Moleculin Biotech Inc Stock Price, Fair Value and News

$4.60+0.08 (+1.77%)
Market Closed

Price Targets

MBRX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

MBRX Price Action

Last 7 days

-3.4%

Last 30 days

33.7%

Last 90 days

-59.3%

Trailing 12 Months

-88.9%

MBRX RSI Chart

MBRX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

MBRX Valuation

Market Cap

234.2M

Price/Earnings (Trailing)

-4.56

EV/EBITDA

-11.28

Price/Free Cashflow

-10.43

MarketCap/EBT

-11.44

MBRX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

MBRX Fundamentals

MBRX Earnings

Earnings (TTM)

-51.4M

Earnings Growth (Yr)

-261.6%

Earnings Growth (Qtr)

-42.62%

MBRX Profitability

Return on Equity

190.98%

Return on Assets

-252.6%

Free Cashflow Yield

-9.59%

MBRX Investor Care

Shares Dilution (1Y)

1595.94%

About Moleculin Biotech Inc

MBRX
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It is also developing WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company was incorporated in 2015 and is headquartered in Houston, Texas.
 CEO
 WEBSITEmoleculin.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES15

Moleculin Biotech Inc Frequently Asked Questions

MBRX is the stock ticker symbol of Moleculin Biotech Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Moleculin Biotech Inc is 234.19 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check MBRX's fair value in chart for subscribers.

The fair value guage provides a quick view whether MBRX is over valued or under valued. Whether Moleculin Biotech Inc is cheap or expensive depends on the assumptions which impact Moleculin Biotech Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MBRX.